Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
Open Access
- 29 October 2013
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 28 (5), 1129-1131
- https://doi.org/10.1038/leu.2013.315
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The clinical significance of cereblon expression in multiple myelomaLeukemia Research, 2013
- Cereblon expression in multiple myeloma: not ready for prime timeBritish Journal of Haematology, 2013
- Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant diseaseBritish Journal of Haematology, 2013
- A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)Leukemia, 2013
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenanceBlood, 2013
- ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in miceBlood, 2012
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010